Angels in MedCity alumnus Sense Biodetection has raised £12.3M to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.
This Oxford based company raised £10.5 million in Series A funding co-led by Cambridge Innovation Capital and Earlybird, with participation from Jonathan Milner and seed round investor Mercia Asset Management. Sense has also secured a grant of £1.8 million from Innovate UK.
“The Angels in MedCity event helped us to define our seed funding strategy and to identify committed and knowledgeable investors.”
Harry Lamble, CEO and co-founder of Sense Biodetection
The company expects the funds to be deployed in the development and manufacture of a range of tests that employ a rapid molecular amplification technology enabling sensitive detection of specific nucleic acids without the need for complex hardware.
Rapid testing for viral and bacterial pathogens, such as those causing respiratory infections or sexually transmitted diseases will be possible with their products. These hardware-free molecular diagnostic tests could be used anywhere, easily adopted by new users and scaled. The testing can take as little as minutes in doctors’ offices, pharmacies, or community facilities, ensuring timely treatment and management of infections.
Harry Lamble, CEO and co-founder of Sense Biodetection said: “The Angels in MedCity event helped us to define our seed funding strategy and to identify committed and knowledgeable investors.”
We are really proud to have been part of Sense Biodetection’s journey and look forward to seeing their progress and their impact in the diagnostics space.